|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastroenteropancreatic neuroendocrine tumours显示文摘 | Irvin M Modlin Kjell Oberg Daniel C Chung Robert T Jensen Wouter W de Herder Rajesh V Thakker Martyn Caplin Gianfranco Delle Fave Greg A Kaltsas Eric P Krenning Steven F Moss Ola Nilsson Guido Rindi Ramon Salazar Philippe Ruszniewski Anders Sundin | 2008 | Lancet Oncology2008，，1： | 8 |
| 2 | Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors显示文摘 | Martyn E. Caplin Marianne Pavel Jaros?aw B. ?wik?a Alexandria T. Phan Markus Raderer Eva Sedlá?ková Guillaume Cadiot Edward M. Wolin Jaume Capdevila Lucy Wall Guido Rindi Alison Langley Séverine Martinez Jo?lle Blumberg Philippe Ruszniewski | 2014 | The New England Journal of Medicine2014，，： | 3 |
| 3 | ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms显示文摘 | Delle Fave Gianfranco Kwekkeboom Dik J Van Cutsem Erik Rindi Guido Kos-kudla Beata Knigge Ulrich Sasano Hironobu Tomassetti Paola Salazar Ramon Ruszniewski Philippe | 2012 | Neuroendocrinology2012，，2： | 3 |
| 4 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts显示文摘AIM: To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts. METHODS: All consecutive patients with histologically confirmed, metastatic PAC and World Health Organiza-tion performance status (PS) ≤ 2 received FOLFIRI-1 [irinotecan 180 mg/m2 on day 1 and leucovorin 400 mg/m2 followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus, then 5-FU 2400 mg/m2 as a 46-h infusion, biweekly] or FOLFIRI-3 (irinotecan 100 mg/m2 on day 1 and leucovorin 400 mg/m2, then 5-FU 2400 mg/m2 as a 46-h infusion and irinotecan 100 mg/m2 repeated on day 3, biweekly) after failure of gemcitabine and platinum-based chemotherapies as a systematic policy in two institutions between January 2005 and May 2010. Tumor response, time to progression (TTP), overall survival rate (OS) and grade 3-4 toxicities were retrospectively studied. Subgroup analyses were performed to search for prognostic factors. RESULTS: Sixty-three patients (52.4% male, median age 59 years) were analyzed. Among them, 42.9% were PS 0, 38.1% were PS 1 and 19.0% were PS 2. Fifty one patients (81.0%) had liver metastases. Before the FOLFIRI regimen, patients had received 1 line (n = 19), 2 lines (n = 39) or 3 lines (n = 5) of chemotherapy. Median TTP obtained with the line before FOLFIRI was 3.9 mo (95% CI: 3.4-5.3 mo). A total of 480 cycles was completed (median: 6 cycles, range: 1-51 cycles). The main reason for discontinuing FOLFIRI was tumor progression (90.3%). Tumor control was achieved in 25 patients (39.7%) (partial response: n = 5, stable disease: n = 20) with FOLFIRI. Median TTP was 3.0 mo (95% CI: 2.1-3.9 mo) and median OS was 6.6 mo (95% CI: 5.3-8.1 mo). Dose adaptation was required in 36 patients (57.1%). Fifteen patients (23.8%) had grade 3-4 toxicities, mainly hematological (n = 11) or digestive (n = 4). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated with poor TTP [hazard ratio (HR): 16.036, P < 0.0001] and OS (HR: 4.003, P = 0.004). CONCLUSION: The FOLFIRI regimen had an acceptable toxicity and an interesting efficacy in our study, limited to patients in good condition (PS 0-1). | Cindy Neuzillet Olivia Hentic Benot Rousseau Vinciane Rebours Léla Bengrine-Lefèvre Franck Bonnetain Philippe Lévy Eric Raymond Philippe Ruszniewski Christophe Louvet Pascal Hammel | 2012 | World Journal of Gastroenterology2012，18，33： | 3 |
| 5 | Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis显示文摘 | B. Bournet A. Souque P. Senesse E. Assenat M. Barthet N. Lesavre A. Aubert D. O’Toole P. Hammel P. Levy P. Ruszniewski M. Bouisson J. Escourrou P. Cordelier L. Buscail | 2009 | Endoscopy2009，，06： | 2 |
| 6 | Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases显示文摘 | Reza Kianmanesh Olivier Farges Eddie K Abdalla Alain Sauvanet Philippe Ruszniewski Jacques Belghiti | 2003 | Journal of the American College of Surgeons2003，，1： | 2 |
| 7 | Natural History of Intraductal Papillary Mucinous Tumors of the Pancreas: Actuarial Risk of Malignancy显示文摘 | Philippe Lévy Vincent Jouannaud Dermot O’Toole Anne Couvelard Marie Pierre Vullierme Laurent Palazzo Alain Aubert Philippe Ponsot Alain Sauvanet Frédérique Maire Olivia Hentic Pascal Hammel Philippe Ruszniewski | 2006 | Clinical Gastroenterology and Hepatology2006，，4： | 2 |
| 8 | Pancreaticoduodenectomy with Mesentericoportal Vein Resection for Adenocarcinoma of the Pancreatic Head显示文摘 | Nicolas Carrère MD Alain Sauvanet MD Diane Goere MD Reza Kianmanesh MD PhD Marie-Pierre Vullierme MD Anne Couvelard MD PhD Philippe Ruszniewski MD Jacques Belghiti MD | 2006 | World Journal of Surgery2006，，8： | 2 |
| 9 | Well-differentiated gastric tumors/carcinomas显示文摘 | Ruszniewski P Delle Fave G Cadiot G | 2006 | Neuroendocrinology2006，84，3： | 1 |
| 10 | Ulcerative colitis in a sigmoid neovagina显示文摘 | Malka D Anquetil C Ruszniewski P | 2000 | N Engl J Med2000，343，5： | 1 |
| 11 | Pancreaticoduodenectomy with Mesentericoportal Vein Resection for Adenocarcinoma of the Pancreatic Head显示文摘 | Nicolas Carrère MD Alain Sauvanet MD Diane Goere MD Reza Kianmanesh MD PhD Marie-Pierre Vullierme MD Anne Couvelard MD PhD Philippe Ruszniewski MD Jacques Belghiti MD | 2006 | World Journal of Surgery2006，，8： | 1 |
| 12 | The long term risk of malignancy in patients with branch duct intraductal papillary mucinous neoplasms of the pancreas显示文摘 | Wafaa Khannoussi Marie Pierre Vullierme Vinciane Rebours Frédérique Maire Olivia Hentic Alain Aubert Alain Sauvanet Safi Dokmak Anne Couvelard Pascal Hammel Philippe Ruszniewski Philippe Lévy | 2012 | Pancreatology2012，，3： | 1 |
| 13 | Predictive factors in the outcome of pseudoeysts complicating alcoholic chronic pencreatitis显示文摘 | Gouyon B Levy P Ruszniewski P | 1997 | Gut1997，41，6： | 1 |
| 14 | Well-differentiated gas-tric tumors/carcinomas显示文摘 | Ruszniewski P Delle Fave G Cadiot G | 2006 | Neuroendocrinology2006，84，3： | 1 |
| 15 | Risk Factors for Diabetes Mellitus in Chronic Pancreatitis显示文摘 | David Malka* Pascal Hammel* Alain Sauvanet* Pierre Rufat? Dermot O'Toole* Pascal Bardet* Jacques Belghiti* Pierre Bernades* Philippe Ruszniewski* Philippe Lévy* | 2000 | Gastroenterology2000，，5： | 1 |
| 16 | Infiltration graisseuse diffuse et primitive du pancréas : une cause rare de stéatorrhée显示文摘 | Alain Aubert Jean-Marc Gornet Pascal Hammel Philippe Lévy Dermot O’toole Philippe Ruszniewski Robert Modigliani Marc Lémann | 2007 | Gastroenterologie Clinique et Biologique2007，，3： | 1 |
| 17 | Well-differentiated gastric tumors/carcinomas显示文摘 | Ruszniewski P Delle Fave G Cadiot G | 2006 | Neuroendocrinology2006，84，3： | 1 |
| 18 | Autoimmune pancreatitis 显示文摘 | Levy P Hammel P Ruszniewski P | 2007 | Presse Med2007，36，12： | 1 |
| 19 | Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy显示文摘 | Sébastien Gaujoux Alexandre Cortes Anne Couvelard Séverine Noullet Laurent Clavel Vinciane Rebours Philippe Lévy Alain Sauvanet Philippe Ruszniewski Jacques Belghiti | 2010 | Surgery2010，，1： | 1 |
| 20 | Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients显示文摘 | Pierre Goudet Arnaud Murat Christine Binquet Christine Cardot-Bauters Annie Costa Philippe Ruszniewski Patricia Niccoli Fabrice Ménégaux Georges Chabrier Fran?oise Borson-Chazot Antoine Tabarin Philippe Bouchard Brigitte Delemer Alfred Beckers Claire Boni | 2010 | World Journal of Surgery2010，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员